FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHA
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section

NGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Bronfeld Zeev (Last) (First) (Middle) 6 URI STREET						Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ORMP.OB] In Date of Earliest Transaction (Month/Day/Year) O9/27/2011 If Amendment, Date of Original Filed (Month/Day/Year)									S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director					
(Street) TEL AVI (City)			54954 Zip)		- 4. 11	4. II Americinent, Date of Original Filed (Month/Day/Year)								Line	X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tabl	e I - N	on-Deriv	<i>r</i> ative	Sec	uritie	s Ac	quire	d, Di	sposed o	f, or E	Benefi	ciall	y Own	ed				
Da				Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 at 5)				5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amount	(A) o (D)	Price	e	Transaction(s) (Instr. 3 and 4)				(11150.4)				
Common	Stock			09/27/	2011				S		350,000	D	\$0	.28	5,808,517 D					
Common Stock															781,250			I	Via DNA Biomedical Solutions Ltd. ⁽¹⁾	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed on Date, (Day/Year)	4. Transa Code (8)		5. Nu of Deriv Secu Acqu (A) of Dispo of (D) (Instrand 5	rative rities ired r osed)	Date Expiration Date (Month/Day/Year) Date Expiration Date Expiration Date Date Exercisable		7. Title and Amount of Securities Underlying Derivative Security (Instr. : and 4) Amount of Number of Shares		3 D S (I	. Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s Illy	10. Ownersh Form: Direct (D or Indirec (I) (Instr.	Beneficial Ownership ct (Instr. 4)		

Explanation of Responses:

1. D.N.A Biomedical Solutions Ltd. ("DNA") owns 781,250 shares of common stock of the Issuer ("Common Stock") and warrants exercisable for 273,438 shares of Common Stock. The Reporting Person holds 23.3% of DNA's outstanding share capital. The Reporting Person and Mr. Meni Mor are parties to a Voting Agreement relating to their shares of DNA, representing, in the aggregate, approximately 46.8% of DNA's outstanding share capital. As a result of the Voting Agreement, the Reporting Person may be deemed a beneficial owner of, and to share the power to vote and dispose, the Issuer securities held by DNA. The Reporting Person disclaims beneficial ownership of any of the Issuer securities held by DNA.

> 09/28/2011 /s/ Zeev Bronfeld

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.